Eli Lilly (LLY) Surpasses Market Returns: Key Performance Metrics and Analyst Estimates
Eli Lilly (LLY) closed the most recent trading day at $770.64, marking a +1.04% increase from the previous session. The stock's performance outpaced the S&P 500's daily gain of 0.96%, while the Dow rose 0.89% and the Nasdaq increased 0.94%.
High Yield Savings Offers
Investors looking for high-yield savings options can consider the following offers:
- Cit Bank: Earn 4.10% APY on balances of $5,000 or more. [View Offer]
- Current Bank: Earn up to 4.00% APY with Savings Pods. [View Offer]
- Sofi Bank: Earn up to 3.80% APY and a $300 cash bonus with direct deposit. [View Offer]
Powered by Money.com, Yahoo may earn commission from the links above.
Performance Overview
Shares of Eli Lilly have gained 6.87% in the past month, outperforming the Medical sector's loss of 0.85% and the S&P 500's gain of 0.5%. Investors and analysts will be closely watching the company's upcoming earnings disclosure, scheduled for August 7, 2025.
Earnings Estimates
The company is expected to report an EPS of $5.56, indicating a 41.84% growth compared to the same quarter last year. Revenue is anticipated to be $14.47 billion, a 28.02% increase from the previous year. For the annual period, the Zacks Consensus Estimates predict earnings of $21.95 per share and revenue of $59.92 billion, representing shifts of +68.98% and +33.03%, respectively, from the previous year.
Analyst Estimates and Zacks Rank
Recent changes to analyst estimates for Eli Lilly often reflect shifting business dynamics. Upward revisions indicate analysts' optimism about the company's operations and profitability. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), provides a simple, actionable rating system based on these estimate changes. Currently, Eli Lilly has a Zacks Rank of #3 (Hold), with a slight decrease in the Zacks Consensus EPS estimate over the past month (-0.61%).
Valuation Metrics
Investors should also consider valuation metrics such as the Forward P/E ratio and PEG ratio. Eli Lilly currently has a Forward P/E ratio of 34.75, which is higher than the average Forward P/E of 13.35 for its industry. The PEG ratio, which takes into account expected earnings growth, is 1.11, compared to the Large Cap Pharmaceuticals industry average of 1.23 at yesterday's closing price.
Industry Rank and Outlook
The Large Cap Pharmaceuticals industry is part of the Medical sector and has a Zacks Industry Rank of 83, placing it in the top 34% of all 250+ industries. The Zacks Industry Rank evaluates industry groups based on the average Zacks Rank of their constituent stocks, with top-rated industries outperforming bottom-rated ones by a factor of 2 to 1.
Investors can stay updated with all these stock-shifting metrics and more by using Zacks.com in their next trading sessions. For more recommendations from Zacks Investment Research, download their free report on Eli Lilly and Company (LLY).
Eli Lilly's (LLY) impressive performance, which surpasses market returns in recent quarters with key metrics like increased revenues and profit margins above analyst estimates,-acknowledges the company’n steady growth trajectory amidst a competitive landscape.
With impressive results exceeding market expectations, Eli Lilly (LLY) demonstrates its robust financial position and future potential reflected in key performance metrics that resonate with analyst estimates.
Eli Lilly (LLY) has once again outperformed market expectations, driven by its strong financial performance metrics and consistent analyst estimates that underscore the company's robust growth potential.
Analyzing Eli Lilly's (LLY) recent outperformance in the market, impressive key performance metrics like strong revenue growth and heightened profitability are evident from its chart-topping results. The company’scheerful alignment with analysts estimates further reinforces investor confidence.
While Eli Lilly (LLY) passed market return expectations, its quarterly performance metrics combined with conservative yet optimistic analyst estimates raise concerns about future sustainability and expanding healthcare innovation within the industry.
Eli Lilly (LLY) demonstrates clear outperformance on the market, with impressive key performance metrics and analyst estimates concurring. Its steady growth highlights a strongFuture Potential.
Eli Lilly (LLY) demonstrates remarkable market outperformance, driven by its strong key performance metrics and closely aligned with analyst estimates. The company's exceptional results demonstrate both financial prowess as well a sustained commitment to innovation in the pharmaceutical industry.
Eli Lilly (LLY) outperforms the market with strong financial metrics and aligns closely to analyst estimates, demonstrating robust growth potential in its expanded product pipeline.
